G. Lichtenstein

Genetics · 2001–2018

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom G. Lichtenstein trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. W. Sandborn
  2. Stefan Schreiber
  3. S. Hanauer
  4. B. Feagan
  5. J. Colombel
  6. P. Rutgeerts
  7. E. Loftus

Who trusts G. Lichtenstein overall

  1. W. Sandborn

Papers from G. Lichtenstein's perspective

Ordered by how strongly the researchers G. Lichtenstein trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. (Gastroenterology)
  2. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. (Gastroenterology)
  3. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (Gastroenterology)
  4. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (Gastroenterology)
  5. A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 (Inflammatory Bowel Diseases)
  6. Inflammatory bowel disease: clinical aspects and established and evolving therapies (The Lancet)
  7. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. (Gastroenterology)
  8. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee (American Journal of Gastroenterology)
  9. Placebo Effects: Biological, Clinical and Ethical Advances (The Lancet)
  10. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. (Clinical Gastroenterology and Hepatology)

Their papers